Roche Plans to Go Toe-to-Toe With Novo, Lilly in Obesity

Roche aims to become a “top three player” in obesity, Teresa Graham, CEO of the group’s Pharma unit, said Thursday during a presentation of the company’s full-year 2025 earnings.

Scroll to Top